ReviewBiophotonics discovery2026
Use of imaging technologies to support complex generic drug development.
Review in Biophotonics discovery, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Significance: Complex drug products remain costly and inaccessible to many patients. The use of modern imaging technologies offers transformative tools to address generic drug research challenges, allowing for improved patient access to safe and effective generic medicines. Aim: This review summarizes imaging research related to a wide range of complex drug products across five coordinated initiatives: high-order characterization of the arrangement of matter in complex products; elucidation of the relationship between the structural features and the functional performance of these dosage forms; establishment of noninvasive approaches to characterize and compare the rate and extent of drug bioavailability from these dosage forms; development of reliable artificial intelligence and machine learning approaches to analyze imaging data; and provision of mechanistic insights to inform the construction of computational models. Results and Conclusions: The technologies summarized in this work enabled non-destructive structural characterization of complex drug products, establishment of structure-performance relationships, and direct measurement of drug availability at local sites of action. Furthermore, currently available technologies used for imaging complex drug products continue to support the establishment of scientifically rigorous, efficient bioequivalence pathways for complex generic products, reducing reliance on costly comparative clinical endpoint studies.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.